• Publications
  • Influence
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
BACKGROUND Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODSExpand
  • 1,233
  • 61
  • PDF
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
CONTEXT Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis. OBJECTIVE To assess the associationExpand
  • 894
  • 29
  • PDF
Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease.
BACKGROUND Patients with obstructive left main coronary artery disease are usually treated with coronary-artery bypass grafting (CABG). Randomized trials have suggested that drug-eluting stents mayExpand
  • 563
  • 28
  • PDF
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.
CONTEXT High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is notExpand
  • 779
  • 25
  • PDF
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial.
AIMS The SYMPLICITY HTN-3 randomized, blinded, sham-controlled trial confirmed the safety of renal denervation (RDN), but did not meet its primary efficacy endpoint. Prior RDN studies haveExpand
  • 376
  • 24
  • PDF
Double negatives.
  • 100
  • 14
  • PDF
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I.
Gregg W. Stone, MD; David E. Kandzari, MD; Roxana Mehran, MD; Antonio Colombo, MD; Robert S. Schwartz, MD; Steven Bailey, MD; Issam Moussa, MD; Paul S. Teirstein, MD; George Dangas, MD, PhD; DonaldExpand
  • 486
  • 13
  • PDF
Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
OBJECTIVES This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-elutingExpand
  • 352
  • 11
Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network
Objectives To investigate the safety and efficacy of durable polymer drug eluting stents (DES) and biodegradable polymer biolimus eluting stents (biolimus-ES). Design Network meta-analysis ofExpand
  • 204
  • 11
  • PDF
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial
BACKGROUND Previous randomised renal denervation studies did not show consistent efficacy in reducing blood pressure. The objective of our study was to evaluate the effect of renal denervation onExpand
  • 330
  • 10